Showing results (511-520 of 532) with videos related to

Sort By:
Pageof 54
Nature Immunology|June 3, 2024
The BTLA-HVEM axis restricts CAR T cell efficacy in cancerPuneeth Guruprasad, Alberto Carturan, Yunlin Zhang, et al.
Cell|March 7, 2026
β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancerShan Liu, Puneeth Guruprasad, Ranjani Ramasubramanian, et al.
Nature Biomedical Engineering|March 10, 2026
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancerGregory M Chen, Ankita Jain, David T Gering, et al.
The New England Journal of Medicine|December 14, 2021
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell LymphomaMichael R Bishop, Michael Dickinson, Duncan Purtill, et al.
Blood|January 6, 2026
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapiesAlberto Carturan, Mathew G Angelos, Puneeth Guruprasad, et al.
Blood Advances|April 9, 2025
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter StudyNikhil Yegya-Raman, John P Plastaras, Christopher M Wright, et al.
Blood|July 28, 2026
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004William G Wierda, Kathleen A Dorritie, Jordan Gauthier, et al.
Blood Advances|May 19, 2019
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLLAnthony R Mato, Lindsey E Roeker, Toby A Eyre, et al.
Blood|January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial updateMartin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.
The Journal of Infectious Diseases|July 25, 2024
Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic LeukemiaElise A Chong, Kingsley Gideon Kumashie, Emeline R Chong, et al.
Pageof 54